Vimarsana
Biggest News Aggregation in the World

Epcoritamab Bysp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Epcoritamab Bysp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Epcoritamab Bysp Today - Breaking & Trending Today

Epcoritamab Receives UK Approval for R/R DLBCL After 2 Prior Lines of Therapy - Vimarsana News

Epcoritamab Receives UK Approval for R/R DLBCL After 2 Prior Lines of Therapy

Published: October 24, 2023

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted conditional marketing authorization to epcoritamab-bysp monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapy.

Source: onclive.com
Related Topics:
United KingdomChris FoxUniversity Of NottinghamHealthcare Products Regulatory AgencyNottingham University HospitalsSchool Of MedicineEuropean CommissionHealthcare Products RegulatoryMedicines And Healthcare Products Regulatory AgencyEpcoritamab ByspDiffuse Largeb Cell LymphomaConditional Marketing AuthorizationEpcore Nhl 1 Trial
Epcoritamab Approved by FDA to Treat R/R DLBCL - Vimarsana News

Epcoritamab Approved by FDA to Treat R/R DLBCL

Published: May 19, 2023

Approval for the T-cell–engaging bispecific antibody came today from the FDA.

Source: ajmc.com
Related Topics:
United StatesTycel PhilipsThomas HudsonDepartment Of Hematology Hematopoietic Cell TransplantationDivision Of LymphomaHematopoietic Cell TransplantationBoxed WarningEpcoritamab ByspRr DlbclBispecific Antibody